Document Classification

Section Type: RESULTS

Text: The annual rate of breast neoplasms (n = 48) was 3. 5 % + / - 1. 0 %, 2. 1 % + / - 0. 8 %, 4. 7 % + / - 1. 3 %, and 5. 2 % + / - 1. 3 % in the tamoxifen, fenretinide, combination, and placebo arms, respectively, with hazard ratios (HRs) of 0. 70 (95 % CI, 0. 32 to 1. 52), 0. 38 (95 % CI, 0. 15 to 0. 90), and 0. 96 (95 % CI, 0. 46 to 1. 99) relative to placebo (tamoxifen x fenretinide adverse interaction P =. 03).